NASDAQ:AEON AEON Biopharma (AEON) Stock Price, News & Analysis $0.73 -0.02 (-2.27%) (As of 03:07 PM ET) Add Compare Share Share Today's Range$0.72▼$0.7750-Day Range$0.74▼$2.9352-Week Range$0.71▼$17.17Volume70,472 shsAverage Volume658,280 shsMarket Capitalization$28.48 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends Get AEON Biopharma alerts: Email Address AEON Biopharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside563.7% Upside$5.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.77) to ($0.69) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.86 out of 5 starsMedical Sector827th out of 927 stocksPharmaceutical Preparations Industry377th out of 425 stocks 3.5 Analyst's Opinion Consensus RatingAEON Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAEON Biopharma has only been the subject of 1 research reports in the past 90 days.Read more about AEON Biopharma's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for AEON. Previous Next 0.0 Dividend Strength Dividend YieldAEON Biopharma does not currently pay a dividend.Dividend GrowthAEON Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AEON. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 4 people have searched for AEON on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added AEON Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AEON Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders20.00% of the stock of AEON Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 22.78% of the stock of AEON Biopharma is held by institutions.Read more about AEON Biopharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AEON Biopharma are expected to grow in the coming year, from ($0.77) to ($0.69) per share. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip?Click Here to learn how to get in now >>> About AEON Biopharma Stock (NASDAQ:AEON)AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.Read More AEON Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AEON Stock News HeadlinesAugust 22, 2024 | finance.yahoo.comAEON Biopharma, Inc. (AEON) Stock Price, News, Quote & History - Yahoo FinanceAugust 19, 2024 | globenewswire.comAEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024September 16, 2024 | Crypto 101 Media (Ad)This Crypto Coin Could 10x FASTER Than BitcoinA shocking leak has revealed Japanese electronics giant Sony is now starting its own blockchain. This move is being made in preparation to onboard all of Sony products (including Sony's Playstation, which captured a record 62% share of the global gaming console market in 2024). Enthusiasts and experts are buzzing with anticipation qnd one little-known crypto coin is poised for RAPID growth as we see this all unfold.August 12, 2024 | globenewswire.comAEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateMay 29, 2024 | markets.businessinsider.comAEON Biopharma Cuts 55% Of Workforce, Terminates CFO To Preserve Cash; Stock Up In Pre-marketMay 29, 2024 | globenewswire.comAEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction PlanMay 15, 2024 | finance.yahoo.comAEON Biopharma, Inc. (AEON)May 14, 2024 | globenewswire.comAEON Biopharma Reports First Quarter 2024 Financial ResultsSeptember 16, 2024 | Crypto 101 Media (Ad)This Crypto Coin Could 10x FASTER Than BitcoinA shocking leak has revealed Japanese electronics giant Sony is now starting its own blockchain. This move is being made in preparation to onboard all of Sony products (including Sony's Playstation, which captured a record 62% share of the global gaming console market in 2024). Enthusiasts and experts are buzzing with anticipation qnd one little-known crypto coin is poised for RAPID growth as we see this all unfold.May 9, 2024 | globenewswire.comAEON Biopharma Provides Update on Development PipelineMay 7, 2024 | markets.businessinsider.comMaintaining Buy on AEON Biopharma: Potential of ABP-450 Despite Phase 2 SetbackMay 3, 2024 | msn.comNewly Listed Migraine-Focused AEON Biopharma Stock Plunges On Friday - Read Here WhyMay 3, 2024 | finance.yahoo.comUS Equity Markets Close Higher Friday Following Weak Jobs ReportMay 3, 2024 | markets.businessinsider.comAEON Says Preliminary Results From Phase 2 Interim Analysis Of ABP-450 Fails To Meet Primary GoalMay 3, 2024 | globenewswire.comAEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic MigraineApril 18, 2024 | markets.businessinsider.comAEON Biopharma: Buoyant Prospects Following FDA Alignment on Migraine StudiesMarch 30, 2024 | globenewswire.comCORRECTION -- AEON Biopharma Announces Redemption of Public WarrantsMarch 29, 2024 | globenewswire.comAEON Biopharma Announces Redemption of Public WarrantsSee More Headlines Receive AEON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AEON Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/12/2024Today9/16/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AEON Previous SymbolNASDAQ:AEON CUSIPN/A CIK1837607 Webwww.aeonbiopharma.com Phone754-220-9229FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+563.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,630,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-240.45% Debt Debt-to-Equity RatioN/A Current Ratio0.39 Quick Ratio0.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($4.12) per share Price / Book-0.18Miscellaneous Outstanding Shares39,122,000Free Float31,298,000Market Cap$29.47 million OptionableNot Optionable Beta0.34 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Marc Forth (Age 53)Principal Financial Officer, President, CEO & Director Comp: $948.75kMr. Alex Wilson (Age 37)Executive VP, Chief Legal Officer & Corporate Secretary Comp: $517.4kDr. Chad K. Oh M.D. (Age 65)Chief Medical Officer Comp: $561kMs. Jennifer Sy (Age 39)Principal Accounting Officer Key CompetitorsAssembly BiosciencesNASDAQ:ASMBFibroBiologicsNASDAQ:FBLGVerastemNASDAQ:VSTMSagimet BiosciencesNASDAQ:SGMTCASI PharmaceuticalsNASDAQ:CASIView All CompetitorsInstitutional OwnershipDavidson Kempner Capital Management LPSold 276,618 shares on 8/14/2024Ownership: 0.230%View All Institutional Transactions AEON Stock Analysis - Frequently Asked Questions How have AEON shares performed this year? AEON Biopharma's stock was trading at $7.20 at the beginning of the year. Since then, AEON shares have decreased by 89.5% and is now trading at $0.7533. View the best growth stocks for 2024 here. How were AEON Biopharma's earnings last quarter? AEON Biopharma, Inc. (NASDAQ:AEON) released its quarterly earnings data on Monday, August, 12th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.03. When did AEON Biopharma IPO? AEON Biopharma (AEON) raised $75 million in an initial public offering (IPO) on Thursday, October 14th 2021. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Who are AEON Biopharma's major shareholders? Top institutional shareholders of AEON Biopharma include Davidson Kempner Capital Management LP (0.23%). View institutional ownership trends. How do I buy shares of AEON Biopharma? Shares of AEON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AEON) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dav...American Hartford Gold Group | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia needs these 3 companies on a new $1 trillion SuperprojectNvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And i...Weiss Ratings | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AEON Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AEON Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.